$62.4 Million is the total value of Polaris Venture Management Co. V, L.L.C.'s 7 reported holdings in Q2 2021. The portfolio turnover from Q1 2021 to Q2 2021 was 12.5% .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
FATE | Fate Therapeutics, Inc. | $49,461,000 | +5.3% | 569,889 | 0.0% | 79.24% | +30.1% | |
LYRA | Lyra Therapeutics, Inc. | $8,840,000 | -30.7% | 1,100,852 | 0.0% | 14.16% | -14.4% | |
XFOR | x4 Pharmaceuticals Inc. | $2,025,000 | -24.5% | 311,492 | 0.0% | 3.24% | -6.7% | |
LIFE | Atyr Pharma Inc. | $637,000 | +9.6% | 130,572 | 0.0% | 1.02% | +35.6% | |
DARE | Sell | Dare Bioscience, Inc. | $617,000 | +12.0% | 326,240 | -0.0% | 0.99% | +38.5% |
GNCA | Genocea Biosciences, Inc. | $462,000 | -13.6% | 197,345 | 0.0% | 0.74% | +6.6% | |
PULM | Pulmatrix, Inc. | $374,000 | -21.8% | 359,441 | 0.0% | 0.60% | -3.4% | |
SELB | Exit | Selecta Biosciences, Inc. | $0 | – | -2,773,479 | -100.0% | -16.27% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-08-12
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
Fate Therapeutics, Inc. | 30 | Q2 2021 | 79.2% |
Atyr Pharma Inc. | 26 | Q3 2021 | 15.1% |
Trevena, Inc. | 22 | Q2 2019 | 24.9% |
Genocea Biosciences, Inc. | 21 | Q1 2019 | 32.5% |
Selecta Biosciences, Inc. | 20 | Q1 2021 | 39.5% |
T2 Biosystems, Inc. | 20 | Q2 2019 | 36.1% |
Dare Bioscience, Inc. | 17 | Q3 2021 | 3.9% |
Pulmatrix, Inc. | 16 | Q1 2019 | 15.4% |
Cerulean Pharma Inc | 13 | Q2 2017 | 16.2% |
Kala Pharmaceuticals, Inc. | 11 | Q1 2020 | 37.1% |
View Polaris Venture Management Co. V, L.L.C.'s complete holdings history.
Latest filings
Type | Filed |
---|---|
3 | 2022-03-30 |
13F-HR | 2021-11-12 |
13F-HR | 2021-08-12 |
13F-HR | 2021-05-12 |
13F-HR | 2021-02-12 |
13F-HR | 2020-11-12 |
13F-HR | 2020-08-12 |
13F-HR | 2020-05-14 |
4 | 2020-05-06 |
3 | 2020-04-30 |
View Polaris Venture Management Co. V, L.L.C.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.